AspirinWorks® Takes the Stage at Pri-Med Southwest 2011

March 23, 2011

PRESS RELEASEFor Immediate Release
AspirinWorks® Takes the Stage at Pri-Med Southwest 2011

Test for aspirin effect is simple and non-invasive

DENVER — March 23, 2011 — Corgenix Medical Corporation (OTCQB: CONX.PK), a worldwide developer and marketer of diagnostic test kits, will be exhibiting and offering complimentary testing for its AspirinWorks® Test at Pri-Med® Southwest 2011 in Houston, Texas.

Corgenix representatives will be on-hand during the conference March 24-26 in booth No. 114 at the George R. Brown Convention Center to answer questions about anti-platelet therapy and testing for the aspirin effect. The AspirinWorks Test will be offered to qualified attendees during regular exhibit hours, and test results will be provided after the conference.

AspirinWorks is a simple, non-invasive lab test performed on a urine specimen, which helps doctors accurately determine aspirin effect in apparently healthy individuals by measuring levels of 11-dehydro thromboxane B2 (11-dhTxB2). High levels of 11-dhTxB2, a metabolite of thromboxane, the target of aspirin therapy, heighten the risk of cardiovascular events, including stroke, myocardial infarction and cardiac death.

Millions of Americans take a daily aspirin to prevent heart attack or stroke but don’t know if the aspirin is having the desired effect. The goal of aspirin therapy is to reduce levels of thromboxane in the blood, decreasing platelet stickiness, and therefore reducing the chance of forming a blood clot.

Launched in the U.S in June 2007 following FDA 510(k) clearance, the AspirinWorks Test is now available nationwide through major medical laboratories, including Quest Diagnostics,

LabCorp, Health Diagnostic Laboratory, Diagnostic Laboratory Medicine and offered locally in the Houston area as the Aspirin Response Test at SpectraCell Laboratories.

Unlike other functional platelet tests that require freshly drawn blood that must be evaluated in five hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor’s office. Physicians and laboratories interested in ordering the test can call 1-800-729- 5661 x180, or email More information is also available at

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’ s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’ s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Company Contact:

Corgenix Medical Corp.
William Critchfield, Senior VP and CFO Phone: 303-453-8903

Media Contact:

Armada Medical Marketing
Dan Snyders, Vice President and Public Relations Supervisor Phone: 303-623-1190 x230